6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carbothioic acid benzylamide | 449798-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carbothioic acid benzylamide
• 英文别名: 6-benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide；N,6-dibenzyl-8-methyl-5,7-dioxo-[1,3]thiazolo[3,2-c]pyrimidine-2-carboxamide
• CAS: 449798-94-1
• 化学式: C₂₂H₁₉N₃O₃S
• 分子量: 405.477
• InChiKey: HKIUSPTWBXDTFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  95
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  双三甲基硅基胺基锂 、 6-benzyl-8-methyl-thiazolo[3,2-c]pyrimidine-5,7-dione 、 异氰酸苄酯 、 氯化铵 在 氮 、 Brine 、 Sodium sulfate-III 、 silica gel 、 二氯甲烷 、 乙醚 作用下， 以 四氢呋喃 、 乙酸乙酯 、 水 为溶剂， 反应 32.38h， 以to give 62 mg (34%) of 6-benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide的产率得到6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carbothioic acid benzylamide
  参考文献：
  名称：

  BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS

  摘要：

  选择性MMP-13抑制剂是公式I的双环嘧啶或其药学上可接受的盐，其中R1为氢或烷基；R2，R3和R4包括氢，卤素，烷基，C≡C（CH2）芳基，CO2烷基，CO2（CH2）芳基，COHN烷基和CONH（CH2）芳基；X为O，S，SO，SO2，CH2，C═O，CHOH，NH或NR5。公式I的化合物或其药学上可接受的盐，可用于治疗癌症或关节炎。

  公开号：

  US20060040957A1

文献信息

• COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB
  申请人：Warner-Lambert Company LLC

  公开号：EP1531904A1

  公开（公告）日：2005-05-25
• COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB
  申请人：WARNER-LAMBERT COMPANY LLC

  公开号：EP1536786A1

  公开（公告）日：2005-06-08
• [EN] BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEINASE DE MATRICE PYRIMIDINE BICYCLIQUE
  申请人：WARNER LAMBERT CO

  公开号：WO2002064599A1

  公开（公告）日：2002-08-22

  Selective MMP-13 inhibitors are bicyclic pyrmidines of the formula or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or alkyl; R?2, R3, and R4¿ include hydrogen, halo, alkyl, C C(CH¿2?)m aryl; and X is O, S, SO, SO2, CH2, C=O, CHOH, NH, OR NR?5¿. A compound of the formula, or a pharmaceutically acceptable salt thereof, is useful for treating cancer or arthritis.
• [EN] COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB<br/>[FR] COMBINAISON D'UN INHIBITEUR ALLOSTERIQUE DE LA METALLOPROTEINASE MATRICIELLE 13 AVEC UN CELECOXIB OU VALDECOXIB
  申请人：WARNER LAMBERT CO

  公开号：WO2004006913A1

  公开（公告）日：2004-01-22

  This invention provides a combination, comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination. This invention also provides a pharmaceutical composition, comprising the invention combination and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.
• [EN] COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB<br/>[FR] COMBINAISON D'UN INHIBITEUR ALLOSTERIQUE DE METALLOPROTEINASE MATRICIELLE 13 AVEC UN INHIBITEUR SELECTIF DE CYCLOOXYGENASE-2, A L'EXCEPTION DU CELECOXIB OU DU VALDECOXIB
  申请人：WARNER LAMBERT CO

  公开号：WO2004007024A1

  公开（公告）日：2004-01-22

  This invention provides a combination, comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, and a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, and a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention further provides a combination, comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSATD, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combinations may also be further combined with other pharmaceutical agents depending on the disease being treated.